Srpska limfomska grupa: demografske karakteristike 257 ispitanika sa folikularnim limfomom

  • Olivera Simonović Clinic for Hematology and Clinical Immunology, Clinical Center Niš, Niš, Serbia
  • Lana Mačukanović - Golubović Clinic for Hematology and Clinical Immunology, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia
  • Boško Andjelić Clinical Center of Serbia, Belgrade, Serbia
  • Darko Antić Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  • Biljana Mihaljević Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
DOI: https://doi.org/10.2298/5342
Ključne reči: lymphoma, follicular||, ||limfom, folikularni, serbia||, ||srbija, predictive value of tests||, ||testovi, prognostička vrednost, combined modality therapy||, ||lečenje, kombinovano,

Sažetak


 

Uvod/Cilj. Folikularni limfom (FL), B-ćelijski tumor obično je indolentnog kliničkog toka bolesti, ali u nekim slučajevima tok bolesti može biti veoma agresivan. Cilj istraživanja bio je da се utvrdi raspodelа bolesnika u prognostičke grupe u odnosu na internacionalni prognostički indeks (IPI) i folikularni limfom internacionalni prognostični indeks (FLIPI) kriterijume, kao i da se odredi značaj klasifikovanja bolesnika u prognostičke grupe koje bi mogle potencijalno uticati na izbor modaliteta lečenja. Metode. Retrospektivno istraživanje izvedeno je na 257 bolesnika sa FL koji su dijagnostikovani od januara 2000. do aprila 2011. Rezultati. Na osnovu IPI prognostičkog indeksa, nizak rizik imalo je 153 (59,53%) bolesnika, srednje nizak rizik 57 (22,18%), srednje visok rizik 15 (5,84%), visoki rizik 9 (3,50%) bolesnika, a nepoznato je bilo svrstavanje 23 bolesnika sa dijagnozom folikularnog limfoma prema IPI. Na osnovu FLIPI prognostičkogi indeksa, nizak rizik imalo je 113 (43,97%), srednji 70 (27,24%), visoki rizik 51 (19,84%), a nepoznato je bilo svrstavanje 23 (8,95%) bolesnika. Na osnovu FLIPI 2 prognostičkog indeksa, nizak rizik imalo je 48 (18,68%), srednji 145 (56,42%), a visoki 41 (15,95%) bolesnika sa FL. Nepoznato je bilo svrstavanje 23 (8,95%) bolesnika. Prema IPI, FLIPI i FLIPI 2 bilo je bolesnika koji zahtevaju lečenje u svim prognostičkim grupama. Zaključak. FLIPI i FLIPI 2 efikasno grupišu bolesnike u grupu visokog rizika i pomažu pri odluci o lečenju za svakog pojedinačnog bolesnika.

Biografija autora

Olivera Simonović, Clinic for Hematology and Clinical Immunology, Clinical Center Niš, Niš, Serbia
specijalista interne medicine, subspecijalista hematolog

Reference

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89(11): 3909−18.

Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U. ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2011; 22(Suppl 6): 59−63.

Agarwal AM, Agarwal N, Glenn MJ, Lim MS. Blastic Transformation of Low-Grade Follicular Lymphoma. J Clin Oncol 2007; 25(16): 2326−8.

Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Ar-ranz-Saez R. Follicular Lymphoma International Prog-nostic Index. Blood 2004; 104(5): 1258−65.

Sehn LH. Optimal use of prognostic factors in non Hodg-kin lymphoma. Hematology Am Soc Hematol Educ Pro-gram. 2006: 295−302.

Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood 2000; 95(3): 783−9.

Kersten MJ, Jong Dd, Raemaekers JM, Kluin PM, Hagenbeek A. Beyond the International Prognostic Index: New prognostic factors in follicular lymphoma and diffuse large-cell lymphomaA meeting report of the Second International Lunenburg Lymphoma Workshop. Hematol J 2004; 5(3): 202−8.

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351(21): 2159−69.

Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105(1): 301−7.

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic in-dex 2: a new prognostic index for follicular lymphoma devel-oped by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27(27): 4555−62.

Anđelić B, Mihaljević B. Prognostic factors in follicular lymphoma. Acta Clin 2010; 10(3): 49−62.

Katzenberger T, Ott G, Klein T, Kalla J, Muller-Hermelinek HK, Ott MM. Cytogenetic alterations affecting bcl6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B cell component. Am J Pathol 2004; 165(2): 481−90.

Stamatopoulos K, Kosmas C, Belessi C, Stavroyianni N, Kyriazopoulos P, Papadaki T. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 2000; 21(6): 298−305.

Gilles AS. Clinical features, prognosis and treatment of follicular lymphoma. ASH Education Book 2007; 216−25.

Coiffier B. First line treatment of follicilar lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Ocol 2005; 3(6): 484−91.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377(9759): 42−51.

Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9(7): 717−20.

Perea G, Altés A, Montoto S, López-Guillermo A, Domingo-Doménech E, Fernández-Sevilla A. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005; 16(9): 1508−13.

Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95(3): 783−9.

Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(5 Suppl 5): 75−88.

Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report on the national LymphoCare study. J Clin Oncol 2009; 27(8): 1202−8.

Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14(4): 1282−90.

Rosenbaum CA. Evolving paradigms in follicular lymphoma: Reevaluating prognostic factors and challenig treatments dogmas. Molec Oncol Rep 2007; 1(2):33-8.

Objavljeno
2015/07/08
Broj časopisa
Vol. 72 Br. 6 (2015)
Rubrika
Originalni članak